(CercleFinance.com) – Biocorp indicates that it has entered into an agreement with Merck KGaA for the development and supply of a specific version of its Mallya device as an accessory for one of the German group’s drug delivery devices.
The device thus developed will automatically keep track of the doses injected using a timestamp and will indicate whether the product has been correctly administered, with the aim of helping patients self-inject and reassuring them.
Merck KGaA will pay up to five million euros for the development during the first three years of collaboration and Biocorp could obtain additional revenues which should reach eight million during the first five years after the launch.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
